Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Immunoadsorption Effect of Arterio-venous ECMO in Refractory Septic Shock With ARDS Following Severe Lung Contusion

NCT04555798 is registered in ClinicalTrials.gov with Mohamed Gaber Allam as lead sponsor.

NCT NCT04555798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04555798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Immunoadsorption Effect of Arterio-venous ECMO in Refractory Septic Shock With ARDS Following Severe Lung Contusion
Lead sponsor
Mohamed Gaber Allam
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2022
Completion date
February 1, 2022
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with respiratory failure and shocked